Show simple item record

dc.contributor.authorUrsinus, Jeanine
dc.contributor.authorVrijmoeth, Hedwig D
dc.contributor.authorHarms, Margriet G
dc.contributor.authorTulen, Anna D
dc.contributor.authorKnoop, Hans
dc.contributor.authorGauw, Stefanie A
dc.contributor.authorZomer, Tizza P
dc.contributor.authorWong, Albert
dc.contributor.authorFriesema, Ingrid H M
dc.contributor.authorVermeeren, Yolande M
dc.contributor.authorJoosten, Leo A B
dc.contributor.authorHovius, Joppe W
dc.contributor.authorKullberg, Bart Jan
dc.contributor.authorvan den Wijngaard, Cees C
dc.date.accessioned2021-10-12T20:10:56Z
dc.date.available2021-10-12T20:10:56Z
dc.date.issued2021-05-27
dc.identifier.pmid34557833
dc.identifier.doi10.1016/j.lanepe.2021.100142
dc.identifier.urihttp://hdl.handle.net/10029/625319
dc.description.abstractOf 1135 LB patients (94•8% erythema migrans, 5•2% disseminated LB), 1084 fulfilled primary analysis criteria, as well as 1942 population and 1887 tick-bite controls. Overall prevalence of persistent symptoms in LB patients was 27•2% (95%CI, 24•7%-29•7%); 6•0% and 3•9% higher than in population (21•2%, 95%CI, 19•3%-23•1%; p < 0•0001) and tick-bite (23•3%, 95%CI 21•3%-25•3%; p = 0•016) cohorts, respectively. At 12 months, fatigue, cognitive impairment, and pain were significantly more severe in erythema migrans patients than in reference cohorts, while in disseminated LB patients, only pain was more severe.en_US
dc.language.isoenen_US
dc.rights© 2021 The Authors.
dc.subjectACA, Acrodermatitis chronica atrophicansen_US
dc.subjectCFQ, Cognitive Failure Questionnaireen_US
dc.subjectCIS, Checklist Individual Strengthen_US
dc.subjectEM, Erythema migransen_US
dc.subjectLB, Lyme borreliosisen_US
dc.subjectPCR, Polymerase Chain Reactionen_US
dc.subjectPHQ-15, Patient Health Questionnaireen_US
dc.subjectPTLDS, Post-treatment Lyme Disease Syndromeen_US
dc.subjectSF-36, SF-36 item Health Surveyen_US
dc.subjectTiC-P, Treatment Inventory of Costs in Patients with psychiatric disordersen_US
dc.subjects.l., sensu latoen_US
dc.titlePrevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study.en_US
dc.typeArticleen_US
dc.identifier.eissn2666-7762
dc.identifier.journalLancet Reg Health Eur 2021; 6:100142en_US
dc.source.journaltitleThe Lancet regional health. Europe
dc.source.volume6
dc.source.beginpage100142
dc.source.endpage
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record